PubMed Health⌕ Search

Biomedical subjects

V M Moiseenko

Publications and source records attributed to V M Moiseenko.

At least 55 records · Page 3Linked to original sources
PubMed1991

[The potential and actual growth rate of breast cancer].

Potential and actual rates of tumor growth were assayed in 13 patients with primary breast cancer. Potential growth rate was calculated according to proliferative activity as assessed by histoautoradiography whereas actual growth--on the basis of changes in tumor size observed on mammograms obtained through the course of the disease. Actual tumor doubling time proved 22.8 times longer (which means that tumors grew slower) than that suggested by proliferative activity. Cell loss at the average rate of 95.5% proved the main reason accounting for the difference. The proliferative activity in regional lymph node metastases measured in 3 patients simultaneously with the primary tumor assay was 3.9 times higher.

Autoradiography↗
PubMed1989

[Growth kinetics of breast cancer].

The rate of breast tumors growth was studied in 71 cases on the basis of tumor measurements taken from successive mammograms. Tumor doubling time (DT) varied 2.9-440 days and averaged 94.1 days (less than 35 days in 18.3; 36-75 days--35.2; 76-110 days--15.1, and 110 days and more--in 30.9% of tumors). Mean age proved shorter in patients with DT of less than 35 days (49.5 +/- 3.1 years) as compared to cases of DT of more than 110 days (55.4 +/- 2.7 years). DT in reproductive patients (77.3 +/- 10.2 days) was significantly lower than in menopausal ones (125.3 +/- 16.6 days) (p less than 0.05). Mean duration of exponential tumor growth till clinical signs development proved 8.35 years with a range of variation from 1.75 to 18.4 years. Terms of tumor development was found to match (+/- 2 years) a number of conditions involving changes in hormonal profile as established on the basis of case history.

Aging↗
PubMed1988

[Work experience of the WHO International Reference Center in assessing the effectiveness of self-examination for the early diagnosis of breast cancer (results of 2 years' research)].

A prospective controlled study of the effectiveness of self-examination for early detection of breast cancer has been conducted in Leningrad since 1985. The study was carried out in a cohort of 90,000 females at 28 in- and outpatient clinics within 24 months. As a result, breast cancer was identified in 82 cases. Mean size of primary tumor proved 1.0 cm less and tumor detected 4.8 months earlier than those with standard diagnostic procedures. The cohort is planned to expand to 150,000 by the end of 1988. Data on correlation between application of self-examination and breast cancer mortality are expected by 1994.

Adult↗
PubMed1988

[Rate of growth of primary cancer of the breast].

Repeated mammography was used to study the rate of primary tumor growth in 64 cases of breast cancer. Primary tumor size doubling time varied 2.9-459 days (98.7 +/- 10.9 days on the average). Four patterns of tumor growth rate were identified: (1) very swift (average doubling time--20.2 days)--in 20.2% of patients; (2) rapid (average doubling time--59.2 days)--37.5% (3) moderate (average doubling time--91.2 days)--14.1%, and (4) slow (average doubling time--212.5 days)--28.1%.

Adult↗
PubMed1987

Breast self-examination for the early detection of breast cancer: a USSR/WHO controlled trial in Leningrad.

Breast self-examination (BSE) is of great potential value for the early detection of breast cancer, especially in areas where mammography and regular examinations by physicians are not practicable. However, BSE cannot be recommended for routine public health practice until there is good evidence that it is effective in reducing mortality from breast cancer. Prospective controlled trials of BSE were therefore initiated in 1985 in Leningrad and Moscow, under the auspices of WHO, in order to establish the value of this potentially cost-effective technique. More than 62 000 women aged 40-64 years have been enrolled in the BSE and control groups in Leningrad and another 88 000 will be added in the next three years. This paper presents the results of the study in Leningrad after the first 15 months.

Adult↗
PubMed1987

[Evaluation of the effect of ovariectomy in patients with stage III breast cancer].

The efficiency of prophylactic ovariectomy and hormone treatment with corticosteroids in patients with primary III degree breast carcinoma was studied. The indices of actuarial survival in the group of patients subjected to ovariectomy (n-115) during the follow-up period from 4 to 15 years proved to be reliably higher (p less than 0.05) as compared with controls (n-145). In determining the upper age limit of the susceptibility to ovariectomy it is expedient to take into consideration the menstrual status: in women it should be performed in premenopause or in the menopause not longer than 5 years.

Adrenal Cortex Hormones↗
PubMed1986

[Adjuvant therapy of breast cancer patients].

The paper discusses the state of the art in adjuvant treatment of breast cancer patients. The protocol of the randomized controlled study of the effectiveness of adjuvant chemohormonotherapy conducted at the Petrov Institute since January, 1985 is presented. It is suggested that all oncological institutions concerned should take part in a cooperative investigation to be carried out along the guidelines outlined in the protocol.

Adult↗
PubMed1986

[Prospective randomized study of the efficacy of adjuvant hormone therapy in patients with breast cancer].

Tentative results of a randomized controlled evaluation of the effectiveness of adjuvant hormonal therapy of breast cancer are discussed. The data on 118 cases examined in 1981-1984 were considered on the basis of menstrual cycle characteristics and extension of tumor. The results obtained as a result of an average 16.9 month-long examination pointed to a relatively higher recurrence incidence in untreated patients and suggested that such studies should be continued. Tolerance evaluation established a higher incidence of side-effects in cases treated with diethylstilbestrol (33.3%) than with tamoxifen (3.8%).

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1986

[Steroid hormone receptors and survival in breast cancer patients].

Estrogen receptor (ER) levels were measured in 280 breast cancer patients (mean age 54.5 years). Progesterone receptor (PR) levels were assayed in 101 of them. 61.4% of cases were at stages I and IIa. No significant difference in 2-year survival was established between ER-negative and ER-positive patients (96.7 and 96.0%, respectively). Two-year survival rate and recurrence--free survival for PR-positive cases were significantly higher than those for PR-negative ones (p greater than 0.05).

Breast Neoplasms↗
PubMed1985

[Adjuvant mono- and polychemotherapy in breast cancer (a randomized study)].

A clinical study started at the Institute in 1975 embraced 1,228 patients with breast tumors of stages I, II and III. Adjuvant monochemotherapy (six courses of 200 mg Thio-TEPA) was followed by a 24.3% decrease in the death rates for the patients with stage I-II tumors (pT0-2N0-1M0), whereas polychemotherapy (six courses of TMF and CMF)-by 32.4%. A 7.8-9.8% increase in corrected survival (as compared with control) was registered in those patients with less advanced malignancies of the breast (pT0-2N0M0) who had received mono- and polychemotherapy. In patients with pT0-2N0-1M0 tumors treated after the TMF or CMF modalities, survival rates showed a 12.0-16.6% increase, as compared with controls, after 6, 7 and 8 years. The beneficial effect of adjuvant chemotherapy (lower mortality rate matched by higher survival) was reliably established in patients under 50 only.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1985

Study of the role of steroid receptors in human breast cancer.

Cytoplasmic estrogen receptors (ER) were studied in 200 female patients with primary breast cancer. Both ER and progesterone receptors (PgR) were studied in 38 patients. Of the 200 tumors, 55% were estrogen receptor-positive, of the 38 tumors, 34.2% were progesterone receptor-positive. The level of steroid receptors was compared with some parameters characterizing the host and the tumor. It was found that the level of ER correlated with the age factors and the menstrual status. The level of ER was higher in women with adrenal or involutive pathogenetic forms of breast cancer and in women with great body weight. There was not found any relation between the level of estrogen receptors and the stage of menstrual cycle as well as between the level of estrogen receptors and the content of sex chromatin in the tumors.

Adult↗
PubMed1985

[Results of phase I study of the effectiveness of self-examination in a program of early detection of breast cancer].

The paper deals with the results of the first phase of a WHO-sponsored study concerned with evaluation of the effectiveness of breast self-examination and carried out in Leningrad. The study was part of a program for early breast cancer diagnosis. 8,000 females were taught the procedure of self-examination. A randomized survey of a representative group of 400 females was conducted during the first 12 months using a special questionnaire. It was intended for evaluating the subjects' comprehension of the aims of the program, their attitude to it and their knowledge on cancer. Due to training as well as regular reminding, the percentage of women who practiced self-examination was as high as 75.1. The results of an analysis of refusals to carry out self-examination are presented.

Adult↗
PubMed1984

[Estrogen receptors in primary breast neoplasms].

Estrogen receptors were studied in 108 stage I and II breast cancer patients aged 28-83. The receptors were identified in 72.6% of cases, 55.5% of tumors being estrogen receptor-positive. Estrogen receptor level and frequency in tumor were found to depend upon patient's age and menstrual function. Mean estrogen receptor levels in patients with adrenal and involutive forms of cancer, which are the most sensitive to hormone therapy were 2-3 times those in ovarian and thyroid forms, the latter being the least sensitive to hormone treatment (ovariectomy + corticosteroids). Scirrhous tumors of the breast in elderly patients were mostly estrogen receptor-positive, this pointing to favorable prognosis in this age bracket.

Adenocarcinoma↗
PubMed1984

[Use of tamoxifen in patients with disseminated and local breast neoplasms].

The efficacy of tamoxifen treatment was studied in 46 postmenopausal patients with localized and disseminated breast cancer. Objective remissions were observed in 47.8, stabilization of tumor process-in 21.7%, mostly in cases of metastasis into the skin, subcutaneous fat, lymph nodes, pleura and bones. Tamoxifen proved sufficiently effective both in primary treatment and as a measure taken when the effect of a specific therapy (radiation, cytostatic or hormonal) was over. Side-effects were slight and were registered in 19.6%.

Adult↗